pamidronate has been researched along with Diabetic Neuropathies in 2 studies
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Naqvi, A | 1 |
Cuchacovich, R | 1 |
Saketkoo, L | 1 |
Espinoza, LR | 1 |
Jude, EB | 1 |
Selby, PL | 1 |
Burgess, J | 1 |
Lilleystone, P | 1 |
Mawer, EB | 1 |
Page, SR | 1 |
Donohoe, M | 1 |
Foster, AV | 1 |
Edmonds, ME | 1 |
Boulton, AJ | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficacy of Treatment With DENOsumab of an Acute CHARCOT Foot in Patients With Diabetes. A Multicenter, Double-blind, Randomized, Placebo-controlled Trial.[NCT04547348] | Phase 3 | 38 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
1 trial available for pamidronate and Diabetic Neuropathies
Article | Year |
---|---|
Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
Topics: Adult; Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthropathy, Neurogenic; Biomarkers; Bo | 2001 |
1 other study available for pamidronate and Diabetic Neuropathies
Article | Year |
---|---|
Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up.
Topics: Aged, 80 and over; Arthropathy, Neurogenic; Bone Density Conservation Agents; Diabetes Mellitus, Typ | 2008 |